Dr. Tom Patterson, Infectious Diseases, was interviewed about the drug remdesivir now entering the third phase of clinical trials at University Hospital, keeping us on the cutting edge of the battle against COVID-19. In this Adaptive COVID-19 Treatment Trial 3, sponsored by the National Institutes of Health, remdesivir will be paired with a drug called interferon beta-1a, which the U.S. Food and Drug Administration has already approved for multiple sclerosis patients.
